Introduction
Rhabdomyolysis is a clinical and biochemical syndrome resulting from skeletal muscle injury and the release of muscle cell constituents into the circulation. It may result in myoglobinuria, the filtration of myoglobin into the urine, and it is often associated with acute renal failure (1) . Drug-induced rhabdomyolysis occurs rarely and may be asymptomatic. However, life-threatening severe electrolyte disorders and acute renal failure may occur in more serious cases (2) . Rhabdomyolysis is the results of an inherited muscle enzyme deficiency, toxins such as alcohol abuse and cocaine, trauma, drugs such as statins, muscle overexertion, infections, and other disorders (3) . Colchicine is a unique anti-inflammatory agent that has been therapeutically used in acute gout for over 230 years. The adverse effects of the drug range from nausea, vomiting, diarrhea, and abdominal pain to agranulocytosis, aplastic anaemia, and alopecia (4) . Colchicine has been reported to cause myoneuropathy (5) and myotonia (6) especially in presence of renal impairment. However, rhabdomyolysis induced by colchicine is rare (7, 8) . Rhabdomyolysis with the use of statin-colchicine combinations has been reported only in one case (9) . Here, we report to our knowledge the second case in literature of a patient who developed rhabdomyolysis after that colchicine was added to statin (fluvastatin) therapy.
Case report
A 77 year old man was admitted to our hospital with complaints of myalgia, nausea, vomiting, and muscle weakness for the last few days. His medical history revealed that percutaneous coronary intervention (PCI) plus drug eluting stent (DES) on left descending coronary artery (LAD) was performed for treatment of critical coronary stenosis 4 years prior. Moreover, he had suffered from chronic pericardial effusion for two years, diabetes mellitus and dyslipidemia for twelve years, arterial hypertension for twenty-five years, chronic renal failure [stage 2 of classification of chronic kidney disease of National Kidney Foundation (10)] for five years and chronic gout for four years. He had used aspirin, beta-blocker, angiotensin-converting enzyme (ACE) inhibitor, nitrates, calcium antagonists, furosemide, insulin and 80 mg a day of fluvastatin for the treatment of coronary artery disease for 4 years. For four weeks before the presentation, he also had been taking colchicine 1.0 mg day for acute gouty arthritis. Fourteen days after initiation of colchicine therapy, the patient started reporting stomach ache and nausea. He later developed increasingly severe pain in anti-dsDNA antibody, and anti-Jo-1 and the serologies for brucellosis, human immunodeficiency virus (HIV), and hepatitis B and C virus were negative. C3 and C4 complement level were normal. Thyroid function tests and anti-thyroid peroxidise (TPO) antibody titer were normal. There were no urinary obstruction findings. During the abdominal ultrasound the size of the liver and kidney were normal. Fluvastatin and colchicine were discontinued. The patient was treated with a infusion of NaCl 0.9% and oral steroid was administered for acute gouty arthritis. As the patient's urine output increased, serum creatine and CK decreased steadily. He was discharged 16 days after admission, feeling well, with CK 85 IU/l, and creatinine 1.34 mg/dl. Fluvastatin was reinitiated after CK level was normalized. Six months later, he was free from symptoms.
Discussion
Statins drop low-density lipoprotein levels and serum total cholesterol and raised high-density lipoprotein levels. Statins are effective in both primary and secondary prevention of ischemic heart disease. As a group, these drugs are well tolerated with a low incidence of side effects. Myopathy occurs in 0.1% to 0.5% of patients (11) .
Adverse effects of statins are frequently associated with drug interactions because of their longterm use in older patients who are likely to be exposed to polypharmacy. In the PRIMO study, 30% of patients that assumed a high-dose of statin therapy that developed muscle-related symptoms, identified the beginning of a new medication as a trigger (12) . Drug interactions involving statins may have either a pharmacodynamic or pharmacokinesic basis, or both. Cytochrome P450 enzymes play an important part in the metabolism of statins, leading to clinically relevant interactions with other agents, particularly cyclosporin, erythromycin, itraconazole, ketoconazole, HIV protease inhibitors, and colchicine, that are also metabolized by this enzyme system. According to Atasoyu and co-workers (9), two different mechanisms may be responsible for the pathogenesis in our patient. Drug interactions that potentiate adverse effects may occur when colchicine is co-administered with fluvastatin since both drugs are metabolized by cytochrome P450 isoenzymes and myotoxic effects are well known (7) (8) . Fluvastatin and colchicine, however, are cleared through two different CYP450 isoenzymes. The second possible mechanism is synergistic myotoxicity (13) . Pathogenesis of colchicine myopathy may be related to the disruption of a cytoskeletal microtubular network that interacts with lysosomes. In addition, fluvastatin therapy is associated with myonecrosis, membranous myeloid bodies, and vacuolization, and all this can disrupt cytoskeletal integrity. The combined use of these drugs may determine a synergistic drug-induced myopathy involving both pharmacokinetic and related pharmacodynamic mechanisms.
Our theory about the causes responsible for muscular side effects in our patient was the addition of colchicine to fluvastin 80 mg, taken for many years (5 years), without any symptom related to the statin treatment. Muscular symptoms appeared only after beginning colchicine treatment. Unfortunately, we began observing the patient only 4 weeks after the treatment with colchicine and due to this reason we were unable to control laboratory parameters before treatment. These data suggested that the side effects were related to the addition of colchicine.
In conclusion, this case highlights a rare but serious and potentially life threatening neuromuscular adverse effect of co-administration of fluvastatin and colchicine. Since pre-existent renal impairment is a predisposing factor for neuromuscular toxicity, cautious dosing of colchicine is warranted in the presence of abnormal baseline renal function.
Physicians should be aware of potentially lethal adverse effects including rhabdomyolysis and acute renal failure after colchicine added to statin therapy. Furthermore, they should carefully follow-up renal, hepatic, and muscle enzymes in all patients. Patients should also be informed about risks of the drugs and about symptoms of potential adverse effects of the drugs such as myalgia and muscle weakness. 
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